Last reviewed · How we verify
Novolin 70/30
Novolin 70/30 is a Insulin combination (intermediate-acting and short-acting) Biologic drug developed by Wockhardt. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels.
Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Novolin 70/30 |
|---|---|
| Sponsor | Wockhardt |
| Drug class | Insulin combination (intermediate-acting and short-acting) |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Novolin 70/30 contains 70% NPH insulin (intermediate-acting) and 30% regular insulin (short-acting). The regular insulin component acts quickly to lower postprandial glucose, while the NPH component provides sustained glucose control throughout the day and overnight. Together, they mimic the body's natural biphasic insulin secretion pattern.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Lipodystrophy
- Weight gain
Key clinical trials
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (PHASE1)
- Effect of Insulin Lowering on Lipogenesis (PHASE1)
- ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (PHASE1, PHASE2)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6 (NA)
- Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novolin 70/30 CI brief — competitive landscape report
- Novolin 70/30 updates RSS · CI watch RSS
- Wockhardt portfolio CI
Frequently asked questions about Novolin 70/30
What is Novolin 70/30?
How does Novolin 70/30 work?
What is Novolin 70/30 used for?
Who makes Novolin 70/30?
What drug class is Novolin 70/30 in?
What development phase is Novolin 70/30 in?
What are the side effects of Novolin 70/30?
What does Novolin 70/30 target?
Related
- Drug class: All Insulin combination (intermediate-acting and short-acting) drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Wockhardt — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing